Catalyst Pharmaceuticals Inc.’s recent filing unveils that its Chief Medical Officer INGENITO GARY unloaded Company’s shares for reported $99718.0 on Dec 06. In the deal valued at $16.85 per share,5,918 shares were sold. As a result of this transaction, INGENITO GARY now holds 30,802 shares worth roughly $ 0.48 million.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Then, Miller Steve sold 20,000 shares, generating $346,740 in total proceeds. Upon selling the shares at $17.34, the Chief Operating Officer now owns 553,791 shares.
Before that, COELHO PHILIP H sold 9,999 shares. Catalyst Pharmaceuticals Inc. shares valued at $174,483 were divested by the Director at a price of $17.45 per share. As a result of the transaction, COELHO PHILIP H now holds 149,553 shares, worth roughly $2.31 million.
ROTH Capital downgraded its Catalyst Pharmaceuticals Inc. [CPRX] rating to a Neutral from a a Buy in a research note published on Friday, August 24, 2022; the price target was increased to $15.50 from $10. PT values the company’s stock at a premium of 0.32 to its Friday closing price. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who began to cover the stock in late September with a ‘”an Overweight”‘ rating. Piper Jaffray revised its rating on October 05, 2016. It rated CPRX as “an Overweight” which previously was an “a Neutral”.
Price Performance Review of CPRX
On Friday, Catalyst Pharmaceuticals Inc. [NASDAQ:CPRX] saw its stock jump 0.98% to $15.45. On the same session, the stock had its day’s lowest price of $15.22, but rose to a high of $15.63. Over the last five days, the stock has gained 1.25%. Catalyst Pharmaceuticals Inc. shares have fallen nearly -16.94% since the year began. Nevertheless, the stocks have risen 91.93% over the past one year. While a 52-week high of $22.11 was reached on 01/13/23, a 52-week low of $6.15 was recorded on 01/23/23. SMA at 50 days reached $17.17, while 200 days put it at $13.25. A total of 0.86 million shares were traded, compared to the trading of 1.35 million shares in the previous session.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 15.24, which if violated will result in even more drops to 15.02. On the upside, there is a resistance level at 15.65. A further resistance level may holdings at 15.84. The Relative Strength Index (RSI) on the 14-day chart is 44.59, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.04, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 40.00%. Stochastics %K at 53.78% indicates the stock is a holding.
How much short interest is there in Catalyst Pharmaceuticals Inc.?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc. stocks on Jan 30, 2023, dropping by -1.88 million shares to a total of 8.63 million shares. Yahoo Finance data shows the prior-month short interest on Dec 29, 2022 was 10.51 million shares. There was a decline of -21.78%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 8.96% of the overall stock float, the days-to-cover ratio (short ratio) fell to 2.57.
Catalyst Pharmaceuticals Inc. [CPRX] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 14,387,502 shares, or roughly 13.83% of the outstanding CPRX shares. In other words, the investor’s shares have risen by 8,480,700 from its previous 13-F filing of 5906802.0. Additionally, SSgA Funds Management, Inc. increased 4.21% of its stake after which the total value it holdings stand at $121,957,634, while The Vanguard Group, Inc. added 10.59% of its stake to hold $101.03 million in the firm. Over the last quarter, Deerfield Management Co. LP purchased 988,448 shares of Catalyst Pharmaceuticals Inc., while Millennium Management LLC bought 873,308 shares. At present, Dimensional Fund Advisors LP is holding 2,308,705 shares valued at $35.76 million. Two Sigma Investments LP owned 1,925,090 shares of the company at the time of its most recent 13F filing, worth $29.82 million.
According to FactSet, Catalyst Pharmaceuticals Inc.’s share price will average $20.90 in the next year, based on opinions of analysts polled by the firm. This is up nearly 43.79 percent from its previous closing price of $15.30. Analysts expect Catalyst Pharmaceuticals Inc. stock to reach the higher price of $24.00, while the lowest price estimate is $15.50. However, 5 analysts have rated CPRX stock as a Buy in their predictions for 2023.